Clik here to view.
Eikon Therapeutics Acquires Global Rights to Clinical-Stage Assets and...
HAYWARD, Calif. Eikon Therapeutics, Inc., a biotechnology company that is advancing breakthrough therapeutics through the purposeful integration of engineering and science, today announced it has...
View ArticleClik here to view.
ライナスバイオ、市場の減速を乗り越え、バリュエーションの回復を背景にシリーズA2で800万ドル追加調達
米ニュージャージー州ノースブランズウィック （ビジネスワイヤ） —...
View ArticleClik here to view.
AOPヘルス:研究結果が真性多血症を対象としたロペグインターフェロンアルファ-2b（ベスレミ）の臨床開発プログラムを後押し
ウィーン ティツィアーノ・バルブイ教授指揮のもと、Fondazione per la Ricerca dell’Ospedale di Bergamo (FROM)が実施したLOW-PV試験の最終結果が「New England Journal of Medicine...
View ArticleClik here to view.
AOP Health：已完成的研究加强了用于真性红细胞增多症的ropeginterferon alpha 2b (BESREMi®)的临床开发计划
维也纳 在Tiziano Barbui教授的领导下，由Fondazione per la Ricerca dell’Ospedale di Bergamo (FROM)进行的LOW-PV研究的最终结果在《新英格兰医学杂志》上发表，AOP Health宣布了一项重要进展，加强了其ropeginterferon alpha-2b...
View ArticleClik here to view.
PharmaEssentia Selects Pint-Pharma as Commercial Partner for BESREMi®...
TAIPEI PharmaEssentia Corporation (TPEx:6446), a leading fully integrated biopharmaceutical company in Taiwan, today announced that it has entered into an exclusive license agreement with...
View ArticleClik here to view.
Signing of Exclusive Distributorship Agreement With EVERZOM
PARIS & TOKYO Summit Pharmaceuticals International (Head Office: Chiyoda-ku, Tokyo; Chief Executive Officer: Katsuya Okuyama; hereinafter “SPI”) has signed an exclusive distributorship agreement...
View ArticleClik here to view.
Bridge Biotherapeutics to Present Tuesday at the BIO International Convention
SEONGNAM, South Korea & CAMBRIDGE, Mass. Bridge Biotherapeutics Inc. (KQ288330), a South Korean clinical-stage biotechnology company focused on developing novel drugs for cancer, fibrosis and...
View ArticleClik here to view.
Vaxxas Announces Interim Results from Phase I Clinical Study of First...
CAMBRIDGE, Mass. & BRISBANE, Australia Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, today announced positive interim results from a Phase I human...
View ArticleClik here to view.
ENHERTU® Demonstrated Clinically Meaningful and Durable Responses in Patients...
TOKYO & MUNICH & BASKING RIDGE, N.J. Positive results from an interim analysis of the ongoing DESTINY-PanTumor02 phase 2 trial showed that ENHERTU® (trastuzumab deruxtecan) demonstrated...
View ArticleClik here to view.
Datopotamab Deruxtecan Combinations Showed Encouraging Tumor Responses in...
TOKYO & MUNICH & BASKING RIDGE, N.J. Updated results from the TROPION-Lung02 phase 1b trial showed that with additional enrollment and follow-up from the initial presentation datopotamab...
View ArticleClik here to view.
MEDiC Life Sciences Announces Collaboration with Bristol Myers Squibb on...
MOUNTAIN VIEW, Calif. MEDiC Life Sciences (“MEDiC”), a Silicon Valley biotech startup, today announced that it entered into a research collaboration with Bristol Myers Squibb (NYSE:BMY). In the...
View ArticleClik here to view.
Transgene and NEC Present New Data on TG4050, an Individualized Cancer...
STRASBOURG, France & TOKYO Regulatory News: Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and NEC...
View ArticleClik here to view.
Amphera Announces a Positive Opinion of the European Medicines Agency on the...
S-HERTOGENBOSCH, Netherlands Amphera B.V., a late-stage biotechnology company developing MesoPher cell therapy to treat cancer, today announces that the EMA Committee for Orphan Medicinal Products...
View ArticleClik here to view.
LUNARピボタル試験で、プラチナ製剤治療後の進行したステージ4のNSCLC患者の全生存期間に統計的に有意で臨床的に意義のある延長を確認
スイス・ロート （ビジネスワイヤ） —...
View ArticleClik here to view.
Exscientia将出席Goldman Sachs第44届全球医疗保健年会
英格兰牛津 (美国商业资讯)–Exscientia plc (Nasdaq: EXAI)今天宣布，Exscientia管理层成员将于太平洋夏令时2023年6月13日（星期二）上午11:20（英国夏令时晚上7:20）参加Goldman Sachs第44届全球医疗保健年会的炉边谈话。 炉边谈话的网络直播可在公司网站的“投资者与媒体”(Investors &...
View ArticleClik here to view.
Exscientiaがゴールドマン・サックスの第44回年次国際医療カンファレンスに出席
英国オックスフォード （ビジネスワイヤ） – Exscientia plc（Nasdaq：EXAI）は、同社経営陣が、2023年6月13日（火）米国太平洋夏時間午前11：20（英国夏時間午後7：20）に予定されているゴールドマン・サックスの第44回年次国際医療カンファレンス座談会に出席することを発表しました。...
View ArticleClik here to view.
Memgen、ASCO 2023年次総会にて、進行性・転移性非小細胞肺癌（NSCLC）におけるMEM-288の新しい臨床データを発表
TAMPA, Fla. （ビジネスワイヤ） — 臨床段階のバイオテクノロジー企業であるMemgen社は、進行性・転移性かつ難治性の非小細胞肺癌患者に対し、腫瘍溶解性ウイルス療法のMEM-288を初めて人体への試験として行い、最新の臨床データを発表しました。Moffittがんセンターの治験研究者主任、Dr. Andreas...
View ArticleClik here to view.
天劢源和宣布双特异性抗体药物A-337 IND获批
中国上海 (美国商业资讯)–天劢源和生物医药（上海）有限公司，一家处于临床阶段的生物技术公司，宣布收到中国国家药品监督管理局（NMPA）颁发的A-337药物临床试验批准通知书。A-337是重组的抗EpCAM-CD3的双特异性抗体，这是一项“开放标签、剂量递增的以评估A-337在晚期实体瘤患者中的安全性和药代动力学的I期临床研究”。...
View ArticleClik here to view.
ITabMed announces the IND approval from NMPA for A-337, a CD3-activating...
SHANGHAI ITabMed Ltd., a clinical-stage biotech company in China, announced the IND approval from China National Medical Products Administration (NMPA) for A-337, a CD3-activating bi-specific...
View ArticleClik here to view.
EpimAb Biotherapeutics Appoints Yonghong Zhu, M.D., Ph.D., as Chief Medical...
SHANGHAI, China EpimAb Biotherapeutics, a clinical stage biotechnology company specializing in the development of bispecific antibodies, today announced the appointment of Yonghong Zhu, M.D., Ph.D.,...
View Article